Julian Adams
Chairman at ELICIO THERAPEUTICS, INC.
Net worth: 24 806 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Connelly | M | 63 |
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 6 years |
| Thomas Bures | M | 49 | 7 years | |
| Robert Ruffolo | M | 74 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 6 years |
| Carol Ashe | F | 66 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 4 years |
| James Geraghty | M | 69 | 7 years | |
| Shawn Tomasello | F | 65 | 5 years | |
| Megan Filoon | F | - | 1 years | |
| Abbey Jenkins | F | - | 2 years | |
| Seth Tasker | M | 45 | 16 years | |
| Anthony Evnin | M | 83 |
Infinity Discovery, Inc.
| 23 years |
| Norman Selby | M | 71 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 21 years |
| Christopher Kiritsy | M | 59 | 8 years | |
| Christopher Haqq | M | 58 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 5 years |
| Allen Nissenson | M | 77 | 4 years | |
| Stephen Wills | M | 67 | 5 years | |
| Annette Matthies | M | 47 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 3 years |
| Kenneth Moch | M | 69 | 8 years | |
| Peter DeMuth | M | 38 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 7 years |
| Yekaterina Chudnovsky | F | 39 | 2 years | |
| Esther Welkowsky | F | - |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 4 years |
| Ann J. Barbier | M | 59 | 6 years | |
| Janice Fukakusa | F | 69 |
Princess Margaret Cancer Foundation
| - |
| Ivan Borrello | M | 60 | 2 years | |
| Karen Wilson | F | 61 | 1 years | |
| Mary Coelho | F | 62 | 1 years | |
| Michael Burns | M | - |
Princess Margaret Cancer Foundation
| 6 years |
| Richard J. Cohen | M | 73 |
Massachusetts Institute of Technology
| 45 years |
| Vladimir Melnikov | M | - | 3 years | |
| Clayton Atto | M | - |
Princess Margaret Cancer Foundation
| - |
| Kayti Aviano | F | - | 7 years | |
| Jack Fleischmann | M | - |
Princess Margaret Cancer Foundation
| - |
| Yona Geffen | M | - | 4 years | |
| Fiorella Kostoris | F | 79 |
Massachusetts Institute of Technology
| 44 years |
| Brian Piekos | M | 49 | 1 years | |
| Andrew Hoffman | M | 62 |
Princess Margaret Cancer Foundation
| 8 years |
| Andrew Irvine | M | 72 |
Princess Margaret Cancer Foundation
| 8 years |
| M. Marianne Harris | F | 66 |
Princess Margaret Cancer Foundation
| - |
| Annie Ropar | F | - |
Princess Margaret Cancer Foundation
| 7 years |
| Ronit Simantov | M | 59 | 7 years | |
| Mary-Alice Vuicic | F | 56 |
Princess Margaret Cancer Foundation
| 10 years |
| John D. Joannopoulos | M | - |
Massachusetts Institute of Technology
| 46 years |
| Stuart Waugh | M | - |
Princess Margaret Cancer Foundation
| 10 years |
| Jochen Tilk | M | 60 |
Princess Margaret Cancer Foundation
| - |
| Joy Seymour | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lawrence Bloch | M | 58 | 11 years | |
| Richard Kogan | M | 81 | 21 years | |
| Jaren Madden | F | - | 7 years | |
| Gerald Quirk | M | 56 | 6 years | |
| Ofer Gonen | M | 49 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 7 years |
| Joshua D. Hamermesh | M | 51 | 3 years | |
| Darlene Deptula-Hicks | F | 66 | - | |
| Franklin H. Moss | M | 75 |
Infinity Discovery, Inc.
| 10 years |
| Christopher M. Lindblom | M | 52 | 8 years | |
| Eric S. Lander | M | 67 |
Infinity Discovery, Inc.
| 15 years |
| Patrick Lee | M | 67 |
Infinity Discovery, Inc.
| 11 years |
| Yael Margolin | M | 70 | 14 years | |
| Mark A. Clements | M | - |
Massachusetts Institute of Technology
| 3 years |
| Steven Kafka | M | 54 | 6 years | |
| Vito Palombella | M | 61 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 14 years |
| Thomas Lynch | M | 63 | 5 years | |
| Heather DiVecchia | F | - | 6 years | |
| Allan Reine | M | 49 | 2 years | |
| Assaf Segal | M | 51 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 1 years |
| Lance Thibault | M | 58 | 1 years | |
| James Tananbaum | M | 60 |
Infinity Discovery, Inc.
| 11 years |
| Steven Holtzman | M | 70 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 18 years |
| Samuel Minzberg | M | 67 |
McGill University
| 11 years |
| Yoo-Hwan Jang | M | 69 |
Massachusetts Institute of Technology
| 3 years |
| Ruben Ojeda | M | - |
Massachusetts Institute of Technology
| 6 years |
| Meryl Zausner | F | 67 | 3 years | |
| Steven C. Webster | M | 67 |
Massachusetts Institute of Technology
| 5 years |
| On-kwok Li | M | 69 |
Massachusetts Institute of Technology
| 3 years |
| Jolie Siegel | F | 47 | 2 years | |
| Lito Ioannidou | F | 70 |
McGill University
| 7 years |
| Juli Morrow | F | 70 |
McGill University
| 4 years |
| Boaz Lifschitz | M | 55 | 5 years | |
| Terence S. Orstlan | M | - |
McGill University
| 6 years |
| Ramie Tritt | M | - |
McGill University
| 7 years |
| Glenn Ives | M | 62 |
Princess Margaret Cancer Foundation
| 9 years |
| J. Wargo | M | 69 |
Massachusetts Institute of Technology
| 6 years |
| José Baselga | M | 65 | 3 years | |
| Chau Khuong | M | 48 | 3 years | |
| Paul Arnison | M | - |
McGill University
| 6 years |
| Caroline Dorsa | F | 64 | 22 years | |
| Richard Bagley | M | 80 |
ProScript, Inc.
 ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a private company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | 4 years |
| André Chabot | M | - |
McGill University
| 5 years |
| Carl M. Ravinsky | M | - |
McGill University
| 5 years |
| Ian Smith | M | 58 | 11 years | |
| Gary Littlejohn | M | 68 |
McGill University
| - |
| Alberta G. Cefis | F | - |
McGill University
| 7 years |
| Huw Nash | M | 57 | 12 years | |
| Marino Carol | F | - | 8 years | |
| Terence S. Ortslan | M | 74 |
McGill University
| 6 years |
| Paul Alofs | M | - |
Princess Margaret Cancer Foundation
| 15 years |
| Bert Richards | M | - |
Massachusetts Institute of Technology
| 5 years |
| Dave Grayzel | M | 56 | 8 years | |
| Brian E. Foody | M | - |
Massachusetts Institute of Technology
| 5 years |
| Jon Hirschtick | M | - |
Massachusetts Institute of Technology
| 5 years |
| Scott Kapnick | M | - | 8 years | |
| Daphne Karydas | F | 49 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 76 | 76.00% |
| Canada | 24 | 24.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Julian Adams
- Personal Network